October 13, 2021 via @iridex_glaucoma
Ophthalmology Times: Advances in cyclophotocoagulation: Good, better, best options outlined
Advancements in laser therapies are changing glaucoma patient treatment for the better, says Shan Lin, M.D. in a recent article by Ophthalmology Times. The article is titled "Advances in cyclophotocoagulation: Good, better, best options outlined.” In it, Dr. Lin shares his opinions about the use of the Iridex G-Probe and MicroPulse P3 Delivery Devices and some of the clinical results he has observed. We invite you to read it!
April 23, 2021 via @iridex_glaucoma
OSN Blog: Concept of procedural glaucoma management evolving
In a recent Ocular Surgery News blog post, Dr. Jason Bacharach of @northbayeye, discusses how the “concept of procedural glaucoma management is evolving” and how non-incisional glaucoma therapy with the MicroPulse P3 Deliver Device has helping him and his patients. He wrote: “Over the years, I have used MicroPulse TLT in both the office and surgical center. The newer probe is perhaps associated with a shorter learning curve; regardless, as my experience with MicroPulse TLT grows, patient outcomes continue to improve. As our practices evolve into a new normal, the viability idea of offering MicroPulse TLT in an office setting may turn out to be a fortuitous lesson learned during the pandemic.” We invite you to read it!
April 7, 2021 via @iridex_glaucoma
Article: A menu of glaucoma treatments includes options to fit all scenarios
An article in Ophthalmology Times by Dr. Michael Giovingo discusses several treatment options glaucoma physicians can provide to their patients, including MicroPulse Laser Trabeculoplasty (MLT), Transscleral Laser Therapy (TLT) with MicroPulse, and Transscleral Cyclophotocoagulation with continuous-wave laser, which are performed using Iridex's devices. He said: "MicroPulse laser trabeculoplasty (MLT) likely provides a similar efficacy compared with SLT but has even less tissue destruction. Unlike SLT, there is no feedback (ie, “champagne bubbles”) when the clinician is applying the laser." About TLT, he said: "The procedure can be performed in-office or in the operating room using the MicroPulse P3 Probe. The benefit of this procedure is that it creates low amounts of inflammation and tissue destruction. Many studies have demonstrated long-term efficacy. The revised MicroPulse P3 Probe is much more ergonomic and has advanced ease of use." We invite you to read it! Read article.
March 12, 2021 via @iridex_glaucoma
Article: Transscleral laser therapy device simplifies procedure
Dr. Jella An wrote an article in Ophthalmology Times titled "Transscleral laser therapy device simplifies procedure" in which she explains her experience treating glaucoma with MicroPulse TLT and the enhancements made to the Iridex MicroPulse P3 Probe. "MicroPulse TLT is my preferred non-incisional procedure for glaucoma patients before proceeding to surgical interventions to potentially reduce the number of drop therapies or address drop failure," she wrote. She concluded with "I have treated my patients with MicroPulse TLT successfully for many years and find it an effective and flexible treatment. I am pleased with the enhancements made to the MicroPulse P3 Device and anticipate continuing to turn to this therapy frequently to treat my patients." We invite you to read it! Read article.
March 2, 2021 @iridex_glaucoma and @iridex_retina
Press Release: Iridex Announces Strategic Collaboration with Topcon Corporation
Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has entered into a strategic collaboration with Topcon Corporation. The transaction provides $19.5 million cash to Iridex, as two leaders join forces in glaucoma and retinal disease treatment. Read press release.
March 2, 2021 @iridex_glaucoma and @iridex_retina
Announcement: Remembering George Marcellino, Iridex's Vice President of Marketing and Clinical Affairs
It is with a heavy heart that Iridex announces that our beloved Vice President of Clinical Affairs and Marketing, George Marcellino, PhD, passed away unexpectedly on February 10, 2021. Read more.
February 22, 2021 via @iridex_glaucoma
Article: MicroPulse P3® Delivery Device featured in The Innovators issue of The Ophthalmologist
The revised MicroPulse P3 Delivery Device was featured in The Innovators issue of The Ophthalmologist and listed as one the innovations in ophthalmology in 2020. The Iridex MicroPulse P3 Delivery Device is a fiberoptic handpiece used with the Iridex Cyclo G6® Laser System to perform MicroPulse® Transscleral Laser Therapy (TLT) – a non-incisional procedure that substantially reduces intraocular pressure for a broad range of glaucoma types including primary open-angle, closed-angle, and refractory glaucomas. Read article.
January 14, 2021 via @iridex_glaucoma
Article: Redesigned Probe Delivers Consistency and Simplification to IOP Reduction
The December issue of Glaucoma Physician Includes an article about the benefits of non-incisional glaucoma therapy and the enhancements made to the IRIDEX MicroPulse P3 Probe. In it, Dr. Brian Francis of Doheny Eye Institute shares how he is using MicroPulse Transscleral Laser Therapy to treat multiple cases of glaucoma and what he thinks of the revised MicroPulse P3 Probe. Read article.
October 12, 2020 via @iridex_glaucoma
Article: MicroPulse Transscleral Laser Therapy an option in refractory glaucoma by Dr. Ronald M.P.C. de Crom
A new article in Ocular Surgery News discusses a study by Dr. Ronald De Crom et al. that shows glaucoma treatment with MicroPulse Transscleral Laser Therapy (TLT) results in fewer serious adverse events compared with traditional glaucoma treatments. Dr. De Crom and colleagues evaluated 141 eyes of 136 patients with primary or secondary glaucoma who underwent standardized MicroPulse TLT and its effect on IOP lowering at 12, 18, and 24 months. Overall, the mean IOP reduction was 27.8%, 24.1%, and 28.6% at 12, 18, and 24 months, respectively. The number of IOP-lowering medications decreased from 3.3 at baseline to 2.2 at 2 years. "MicroPulse TLT is a good and safe treatment option, especially in patients after failed incision glaucoma surgery or in patients with a high risk of incision surgery,” said Dr. De Crom. Read article.
September 30, 2020 via @iridex_glaucoma and @iridex_retina
IRIDEX at the virtual ESCRS 2020 Congress
We are looking forward to connecting with you at the virtual congress of The European Society of Cataract and Refractive Surgeons (@escrs) this Friday, October 2nd - Sunday, October, 4th! We will provide information and resources related to our glaucoma and retina products and therapies. During virtual exhibit hours, we will also be connected via Zoom and available to speak live. More details at Iridex.com/escrs.
September 28, 2020 via @iridex_retina
Blog: Long-term durability of MicroPulse laser treatment by Dr. Caesar Luo
In his latest Ocular Surgery News blog post, Dr. Caesar Luo shares his results after using the IQ 532 laser in MicroPulse mode to treat a patient with branch retinal vein occlusion and macular edema. He wrote: "The topic of durability is more relevant now than it ever has been. A young professional patient of mine with branch retinal vein occlusion and macular edema had been receiving monthly anti-VEGF injections over 2 years with great success. She was 20/20 with the treatments and happy with her vision, but making it to the monthly appointments was a burden due to the drive as well as taking time off work. We discussed MicroPulse laser therapy as a treatment option. After one MicroPulse session, utilizing a 532 nm green laser in a confluent pattern over the fovea, I didn’t need to treat her again for more than a year — either with pharmacotherapy or laser. She was able to extend her follow-up visits to once every 3 to 4 months, significantly reducing the treatment burden and improving her quality of life." Read blog.
September 14, 2020 via @iridex_glaucoma
Webinar: MicroPulse Transscleral Laser Therapy for Glaucoma by Dr. Rajen Desai
In this webinar, Dr. Rajen Desai discusses his results treating glaucoma with MicroPulse Transscleral Laser Therapy (TLT) utilizing the MicroPulse P3 Probe. "This [webinar] is not a talk about the traditional cyclophotocoagulation we are used to. This is a talk about MicroPulse TLT. I have performed over a hundred MicroPulse TLT procedures, and have not experienced a single case of iritis or CME. MicroPulse TLT is safe, effective, and can be done in the office and OR in less than 5 minutes. I'll share my experience using MicroPulse TLT standalone on 20/20 eyes or combined with cataract surgeries, MIGS cases, and tube shunt implantations. For surgeons who may not feel comfortable adopting the newest MIGS devices but want something effective and safe to reduce IOP with the simplest learning curve, MicroPulse TLT is an outstanding option," said Dr. Desai. Watch webinar.
August 5, 2020 via @iridex_glaucoma
Article: Cyclophotocoagulation in Pediatric Glaucoma by Albert S Khouri, MD
In a recent article published in EyeWiki, Dr. Albert Khouri discussed the use of laser therapy in pediatric glaucoma; in continuous-wave mode with the Iridex G-Probe and in MicroPulse mode with the Iridex MicroPulse P3 Probe. "Cyclophotocoagulation is generally considered a safe procedure in the treatment of refractory pediatric glaucoma. MicroPulse CPC delivers less energy and may be a safer modality than continuous-wave CPC due to its on and off cycles allowing for less thermal effects," wrote Dr. Khoiri. We invite you to read the article.
July 23, 2020 via @iridex_glaucoma
Glaucoma Specialists Discuss the Evolution And The Versatility Of Non-Incisional MicroPulse® Transscleral Laser Therapy
In the June issue of Glaucoma Physician, you can find an article highlighting key messages from webinars we recently had with Doctors Jason Bacharach, Brian Francis, Syril Dorairaj, Michael Giovingo, Brian Jerkins, Nathan Radcliffe, and Sandra Sieminski. The surgeons discussed the benefits and evolution of MicroPulse Transscleral Laser Therapy, including its use during the COVID-19 pandemic. The webinars covered how surgeons use MicroPulse TLT to achieve effective clinical outcomes in a variety of glaucoma types and severity, the ergonomic improvements of the revised MicroPulse P3 Device, and best practices for performing the procedure. We invite you to read it.
July 18, 2020 via @iridex_glaucoma
Study: The Effectiveness and Safety of Micropulse Cyclophotocoagulation in the Treatment of Ocular Hypertension and Glaucoma
A new peer-reviewed study was recently published in AAO's Ophthalmology Glaucoma Journal. Darana Yuen, MD et al. of the University of Toronto evaluated the effectiveness and safety of primary and adjunctive MicroPulse Transscleral Laser Therapy (TLT) in the treatment of ocular hypertension (OHT) and glaucoma. Three hundred ninety-nine surgeries, on 342 eyes of 214 patients, were analyzed. No patients demonstrated persistent inflammation or hypotony, phthisis bulbi, or sympathetic ophthalmic. They concluded that MicroPulse TLT demonstrated effectiveness and safety in IOP reduction sustained to 1 year. Learn More.
July 6, 2020 via @iridex_glaucoma
Webinar: MicroPulse Transscleral Laser Therapy in Canada
On behalf of Salient Medical Solutions, our distributor in Canada, we invite you to a webinar taking place this Tuesday, July 7th at 7:00pm Eastern Time. Doctors Nir Shoham-Hazon MD, Darana Yuen, Patrick Gooi, Toby Chan, and Paul Harasymowycz will be sharing experiences and discussing best practices when treating glaucoma with non-incisional MicroPulse Transscleral Laser Therapy. Register here.
May 11, 2020 via @iridex_glaucoma
Webinar: Evolución De La Terapia MicroPulse Para Glaucoma: Un Tratamiento Versátil (Primera Parte)
Hemos preparado dos excelentes webinars es español para Latinoamérica. Invitamos a todos los oftalmólogos a participar. La primera parte se llevará acabo el 14 de mayo. Los doctores Tomas M. Grippo (Argentina), Vanessa Liberato (República Dominicana), Vital Paulino Costa (Brasil), Francisco Ortega (México), y María Fernanda Delgado (Colombia) hablaran sobre la evolución y la versatilidad de la terapia MicroPulse para glaucoma. Entre otros temas, se hablara sobre como funciona la terapia MicroPulse para glaucoma, que dicen los estudios sobre la seguridad y efectividad, que tipo de pacientes pueden ser considerados, como se puede utilizar durante la pandemia COVID-19, y porque se cambio la sonda y cuales son los beneficios." Los invitamos. Regístrate aquí.
May 10, 2020 via @iridex_glaucoma
Article: MicroPulse Transscleral Laser Therapy After Tube Shunt Surgery by Brian Jerkins, MD
In the March/April issue of Glaucoma Today, Brian M. Jerkins, MD discusses why he uses MicroPulse Transscleral Laser Therapy after tube shunt surgery and shares his outcomes after treating patients in his clinic. He wrote: "With a quick recovery time (a few days to a week at most) and minimal risk of hypotony, this treatment is a safe and effective alternative to placing a second implant. Approximately 87% of patients with a failed tube shunt who underwent MicroPulse therapy achieved a greater than 20% reduction in IOP, with 62.5% achieving an IOP reduction of greater than 30% (range, 0%–80%). MicroPulse TLT shows promise for surgeons who wish to avoid further invasive procedures. It also works well in tandem with tube shunt implants before primary implantation. Overall, the procedure is straightforward and fast, with easy recovery and minimal complication rates." We invite you to read it.
April 23, 2020 via @iridex_corporation
Case: A Case of Iridocorneal Endothelial Syndrome
In a case file published in Glaucoma Physician, Matthew Rouse, MD shared how he used MicroPulse Transscleral Laser Therapy (TLT) to help a 30-year-old female patient with iridocorneal endothelial syndrome (ICE) and elevated intraocular pressure (IOP). He wrote: "At the height of her drop therapy, she was taking 5 different classes of topical medication to manage her disease... There was a desire to avoid the use of antifibrotics in a young female with an active lifestyle... The decision was made to treat her glaucoma with MicroPulse TLT... At her 6-month postoperative visit, her vision was 20/25 in the affected eye with an IOP of 8 mmHg on dorzolamide-timolol drops BID. She had also noted a decrease in ocular irritation and redness. MicroPulse TLT is an effective treatment for refractory glaucoma and appears to have increased success in eyes with previous filtration surgery with relatively low complication rates." We invite you to read it.
April 20, 2020 via @iridex_corporation
Study: Micropulse Transscleral Laser Therapy in Refractory Glaucoma
A study by Brian A. Francis, MD, MS, Giancarlo A. Garcia, MD, Aleksandr Yelenskiy, MD et al. assessed the short-term efficacy and safety of MicroPulse Transscleral Laser Therapy (TLT) in the management of refractory glaucoma and compared outcomes based on prior glaucoma surgeries. The study concluded that Micropulse TLT has a significant short-term ocular hypotensive effect and favorable safety profile in eyes with refractory glaucoma. The probability of a successful outcome was greater in eyes that had undergone prior traditional glaucoma surgery. We invite you to read it.
April 1, 2020 via @iridex_corporation
Webinar: The revised MicroPulse P3® Device: What You Need to Know
Join us on Monday, April 13th at 5:30pm (Pacific Time) to learn about the enhancements made to the design of the MicroPulse P3 Device and the treatment parameters. Dr. Michael Giovingo will share with us his opinion of the ergonomics, features, and benefits of the revised MicroPulse P3 Device and will discuss his experience utilizing MicroPulse® Transscleral Laser Therapy in a wide variety of glaucoma cases. Register.
March 24, 2020 via @iridex_corporation
IRIDEX Glaucoma Training
To facilitate online training in lieu of physical interactions, we have developed a web page to provide clinical and technical information, a tutorial video, and resources related to the MicroPulse P3® Device. This web page can help ophthalmologists with their preparation to perform non-incisional glaucoma treatment with MicroPulse® Transscleral Laser Therapy. Visit page.
March 24, 2020 via @iridex_corporation
Webinar: How Dr. Jason Bacharach is Treating Glaucoma During the COVID-19 Pandemic
At IRIDEX, we are grateful for the physicians delivering care during this challenging time. To facilitate the exchange of treatment ideas, we have prepared an educational live webinar with Dr. Jason Bacharach of North Bay Eye Associates (California), and we invite all glaucoma specialists to participate. Dr. Bacharach will share how he is treating glaucoma during the COVID-19 pandemic and how he is adjusting to the cancelation of elective surgeries. This will be a great opportunity to learn about non-incisional glaucoma therapy, chat with other ophthalmologists, and to exchange ideas for monitoring patients while maintaining social distancing. The webinar is on Thursday, March 26th at 5:30pm (Pacific Time). Learn more.
March 23, 2020 via @iridex_corporation
Video: Tratamiento de glaucoma con terapia MicroPulse de IRIDEX - Dra. Maria Fernanda Delgado
La Dra. María Fernanda Delgado de Colombia presentando sus experiencias y resultados tratando glaucoma con la terapia MicroPulse de IRIDEX. Esta presentación la dio en el congreso Facocaribe 2020. Habla de estudios, técnica, eficacia, y de los cambios que se le hicieron a la sonda MicroPulse P3. Ver video.
March 5, 2020 via @iridex_corporation
The revised MicroPulse P3 Device featured on the latest episode of EyeWire News
The revised MicroPulse P3® Device for non-incisional glaucoma therapy was featured on the latest episode of EyeWire News. We invite you to watch it to learn about the enhancements made to the design. Watch video.
February 27, 2020 via @iridex_corporation
IRIDEX Launches Revised MicroPulse P3® Device for Glaucoma
We are happy to announce the launch of the revised MicroPulse P3® Device for non-incisional glaucoma therapy! The device has been redesigned to deliver greater stability, visualization, coupling, and fit. “The launch of our revised MicroPulse P3 Device represents an important step forward in simplifying our unique non-incisional glaucoma therapy. We are pleased with the initial physician users’ positive response to the product improvements,” said David Bruce, CEO of IRIDEX. We invite you to read press release.
February 12, 2020 via @iridex_corporation
Double-Session Micropulse Transscleral Laser (CYCLO G6) as a Primary Surgical Procedure for Glaucoma
A study titled "Double-Session Micropulse Transscleral Laser (CYCLO G6) as a Primary Surgical Procedure for Glaucoma" by Dr. Leopoldo Magacho, Dr. Francisco Lima, and Dr. Marcos Avila was recently published in the Journal of Glaucoma. In conclusion, they wrote: "Double-session MP3 therapy could be considered as a safe and effective procedure to treat glaucoma in eyes that have not undergone any previous glaucoma surgery." We invite you to read the study.
January 3, 2020 via @iridex_corporation
Outcome Of MicroPulse® Transscleral Photocoagulation in Different Types of Glaucoma
A new study about the safety and efficacy of MicroPulse transscleral cyclophotocoagulation in patients with various types of glaucoma was published in the Clinical Ophthalmology Journal. The study is by Dr. Ahmed AL Habash of Saudi Arabia and in it he evaluated patients for up to 24-months. "MicroPulse® Transscleral Photocoagulation demonstrated good efficacy and safety profiles with minimal vision-threatening complications in treating a variety of glaucoma types," is Dr. Ahmed AL Habash's conclusion. We invite you to read the study.
December 9, 2019 via @iridex_corporation
Micropulse Transscleral Laser Therapy for Glaucoma: A potential noninvasive therapy for mild-to-moderate cases
"MicroPulse Transscleral Laser Therapy for Glaucoma: A potential noninvasive therapy for mild-to-moderate cases" is the title of an article by Dr Vital Paulino Costa in the December issue of Glaucoma Physician. In it, Dr. Costa shares tips and explains why and when he uses MicroPulse Therapy. He also wrote: “In my experience, MicroPulse TLT has been a virtually risk-free intervention for patients with high IOP.” read article
December 5, 2019 via @iridex_corporation
Outcomes of MicroPulse Transscleral Cyclophotocoagulation in Eyes With Good Central Vision
A new peer-reviewed study about the safety and efficacy of MicroPulse Transscleral Therapy was recently published in the Journal of Glaucoma. This study is the first to report MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC) use in only good vision patients. MicroPulse TSCPC significantly reduced intraocular pressure (IOP) and glaucoma medication use without any significant reduction in visual acuity at every postoperative follow-up point. Dr. Sandra Sieminski of Ross Eye Institute, Dr. Syril Dorairaj of Mayo Clinic, et. al. concluded that "MicroPulse TSCPC should be considered earlier in the management of glaucoma and can possibly be offered as an alternative to incisional glaucoma surgeries".... read article
October 30, 2019 via @iridex_corporation
Article by Dr. Nir Shoham-Hazon in The Ophthalmology highlights MicroPulse transscleral therapy
In the October issue of The Ophthalmologist, Nir Shoham-Hazon MD wrote an article titled "Finger on the Pulse. In favor of MicroPulse transscleral cyclophotocoagulation for glaucoma mild – and wild." In it, he mentions: "In my practice, the addition of the MicroPulse transscleral cyclophotocoagulation (MP-TSCPC) procedure with the MicroPulse P3 probe and the Cyclo G6 Glaucoma Laser (Iridex) has proven to be a safe, effective and reliable approach for lowering IOP. Personally, I have used MP-TSCPC on patients with what I would call mild to wild glaucoma – and for good reason. It is safe and effective without yielding major impact on the target tissue, and it’s repeatable if necessary".... read article
October 10, 2019 via @iridex_corporation
IRIDEX at AAO 2019 in San Francisco
Join us at AAO! There will be several opportunities to learn about MicroPulse therapy. Twenty-one physicians will share experiences and provide feedback at our booth, two wetlands sessions will be featured MicroPulse Transscleral Therapy, and it will be discussed in several posters.... learn now
September 30, 2019 via @iridex_corporation
Live webinar with Brian Francis, MD, MS on Thursday, October 3rd
Our next live webinar about MicroPulse Therapy for glaucoma will take place this Thursday, October 3rd at 5:30pm (pacific time). Dr. Brian Francis of Doheny Eye Institute UCLA will share how he is utilizing MicroPulse® Transscleral Laser Therapy in patients with maximum tolerated medical therapy and compliance issues. He will also share experiences, outcomes, provide feedback, and answer questions from the audience. Technique, proper parameters, and best practices will also be discussed. If this time does not work for you, register now and we will send you a link to the webinar recording once it is ready.... register now
September 11, 2019 via @iridex_corporation
MicroPulse® Transscleral Laser Therapy Will be Discussed in Various Presentations and Events at ESCRS
We are happy to announce that MicroPulse® Transscleral Laser Therapy will be featured prominently in various presentations and educational events at the 2019 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Paris, France on Friday, September 13 through Wednesday, September 18... read more
September 2, 2019 via @iridex_corporation
Meet MicroPulse TSCPC experts at ESCRS 2019 in Paris
Join us at booth C125 at ESCRS to speak with glaucoma specialists in one-on-one casual conversations about their experience treating glaucoma with non-incisional MicroPulse Transscleral Laser Therapy and the MicroPulse P3 probe. This is a great opportunity to ask them questions about patient selection, technique, outcomes, complications, their research, and the safety and efficacy of the procedure. Learn more
September 1, 2019 via @iridex_corporation
MicroPulse TSCPC Lunch Symposium at ESCRS 2019 in Paris
We invite ophthalmologists attending the ESCRS Congress in Paris to a lunch symposium on Sunday, September 15th to learn how six world-renowned glaucoma specialists are using non-incisional MicroPulse® Transscleral Cyclophotocoagulation to treat multiple cases of glaucoma. They will share why they consider this glaucoma therapy to be safe, effective, durable, and versatile. This will be a great opportunity to ask questions and to learn about the latest in studies, clinical cases, technique, and patient selection. We look forward to seeing you there! Learn more
August 27, 2019 via @iridex_corporation
MicroPulse Versus Continuous-wave Transscleral Cyclophotocoagulation in Refractory Pediatric Glaucoma
“A study by Dr. Ahmed M. Abdelrahman and Dr. Yasmine M. El Sayed published in the Journal of Glaucoma compares MicroPulse with Continuous-wave transscleral cyclophotocoagulation in refractory pediatric glaucoma, and it concludes that "the rate of complications, pain, and inflammation seem to be lower with MicroPulse mode, making it a safer alternative for cyclophotocoagulation, especially since retreatments are often needed..." read article
August 16, 2019 via @iridex_corporation
MicroPulse cyclophotocoagulation effective in keratoplasty eyes
“This study demonstrated that MicroPulse can lower IOP significantly in a manner that is less traumatic and inflammatory than other modalities such as traditional transscleral cyclophotocoagulation,” says Dr. Robert Noecker in the August issue of EyeWorld magazine in which he discusses MicroPulse transscleral cyclophotocoagulation as an effective treatment for patients with keratoplasty eyes... read article
August 13, 2019 via @iridex_corporation
Webinar with Dr. Nathan Radcliffe: Optimizing MicroPulse TSCPC for Multiple Glaucoma Types
Our latest webinar is now available on-demand. Dr. Nathan Radcliffe discusses how he optimizes the MicroPulse® Transscleral Cyclophotocoagulation procedure to treat multiple glaucoma types. He talks about clinical cases, his research, and how he uses it in combination or as an alternative to other glaucoma treatments. He also answers questions from ophthalmologists for more than 30 minutes... watch webinar
August 12, 2019 via @iridex_corporation
Article: Laser therapy maintains position as key DME treatment option
“Laser still plays a very important role in the treatment of diabetic macular edema (DME) despite our reliance on anti-vascular endothelial drugs,” said Elias Reichel, MD in a recent Ophthalmology Times article... read article
August 7, 2019 via @iridex_corporation
Transscleral MicroPulse CPC in Open-Angle Glaucoma
"MicroPulse transscleral cyclophotocoagulation is an emerging technology with good initial results for IOP reduction in patients with refractory glaucoma. My clinical experience and results from our study allow me to comfortably utilize MP-TSCPC as a safe and effective method of reducing IOP in refractory glaucoma, with sustainable IOP-lowering benefits in open-angle patients specifically," said Dr. Rohit Krishna and Dr. Fahad Khan in an article published by Glaucoma Today...read article
April 22, 2019 via @iridex_corporation
How does wavelength factor into choosing a laser?
In an Ocular Surgery News blog post titled "How does wavelength factor into choosing a laser?", Dr. Caesar Luo of Bay Area Retina Associates (California) wrote: "Purchasing a laser for your practice is a significant capital investment, but when chosen wisely, it has the potential to generate a significant return..... In my opinion, a standard 532 nm or 577 nm laser can really serve the needs of most practices.... From a purely practical standpoint, the IRIDEX IQ 577 laser system offers the best of the 532 nm and 577 nm wavelength in one unit"...read more
April 15, 2019 via @iridex_corporation
Webinar: The role of MicroPulse TSCPC for your glaucoma patients
We invite ophthalmologists to a live webinar titled "The role of MicroPulse TSCPC for your glaucoma patients" on April 23rd at 6:00pm (Pacific Time) to learn innovative treatment pearls from Dr. Brian Jerkins of UTHSC Hamilton Eye Institute in Memphis. He will share wow he is using the non-incisional Cyclo G6 Glaucoma Laser System to treat a wide variety of glaucoma cases, and why he is using it prior to, in conjunction with, or after other glaucoma treatments.... learn more
March 27, 2019 via @iridex_corporation
MicroPulse Laser Therapy Featured in USA Today Supplement
In today’s issue of USA Today, a supplement with vision and hearing topics is featuring MicroPulse Laser Therapy and describes how it can be an alternative to eye drops and invasive surgeries for glaucoma treatment. In it, Dr. Ahad Mahootchi says: “I regularly treat a wide variety of glaucoma patients with it, and my patients are very happy with the results”.... read more
March 25, 2019 via @iridex_corporation
Speak with MicroPulse Laser Experts at World Glaucoma Congress
We invite you to our booth to speak with glaucoma specialists about their experience treating a wide variety of cases with the Cyclo G6 Laser in MicroPulse laser mode. This is a great opportunity to ask them questions about cases and results in one-on-one casual conversations. No appointment necessary. Simply stop by the booth and speak directly with them. Dr. Ziad Khoueir (Wednesday), Dr. Sandra Sieminski (Thursday), Dr. Shan Lin (Thursday), Dr. Robert Chang (Friday), Dr. Sheng Lim (Friday), Dr. Vital Paulino Costa (Saturday)... read more
March 19, 2019 via @iridex_corporation
MicroPulse TSCPC Wet Lab at World Glaucoma Congress
We invite ophthalmologists attending the World Glaucoma Congress in Melbourne, Australia to a wet lab on March 29th from 1:45pm - 3:15pm to learn about treating glaucoma with the Cyclo G6 Laser in MicroPulse laser mode. Attendees will learn about the latest clinical evidence, technique, patient selection, case results, and will get trained by eight world-renowned glaucoma specialists: Prof. Paul Chew (Singapore), Dr. Ziad Khoueir (Lebanon), Dr. Shan Lin (United States), Dr. Robert Chang (United States), Dr. Sandra Sieminski (United States), Dr. Victor Koh (Singapore), Cecilia Aquino (Singapore) and Ilesh Patel (Australia). Space is limited... read more
March 6, 2019 via @iridex_corporation
Dinner and Clinical Discussion at AGS with Dr. Shan Lin
We invite ophthalmologists to a dinner and clinical discussion with Dr. Shan Lin at the American Glaucoma Society (AGS) annual meeting in San Francisco to learn how and why he is treating a wide variety of glaucoma cases with the Cyclo G6 Laser System in MicroPulse laser mode. Dr. Lin will discuss his experience and clinical research of MicroPulse laser therapy, and why he is using it in addition or as an alternative to medications and invasive surgeries. The dinner will be on Wednesday, March 13th at 7:00pm at One Market Restaurant... read more
March 1, 2019 via @iridex_corporation
Subthreshold Laser Treatment for Macular Edema in Retinal Vein Occlusion
In the January issue of Retina Today, Dr. Matteo Forlini examines the role of subthreshold laser in the era of anti-VEGF and discusses the effectiveness of MicroPulse laser with the IRIDEX IQ 577 Laser. After sharing details and results of a case, he says: "Subthreshold MicroPulse Laser Photocoagulation (SMLP) may be effective in patients with macular edema secondary to BRVO, especially in refractory cases... we saw no evidence of local or systemic side effects of laser therapy..." read more
February 13, 2019 via @iridex_corporation
The role of Micropulse Therapy - Article by Dr. Ahad Mahootchi
In the February issue of Ophthalmology Management, Dr. Ahad Mahootchi of the Eye Clinic of Florida says: "I frequently make use of MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC). In more than 300 patients who have received MP-TSCPC with the Cyclo G6 Glaucoma Laser in my clinic, 95% are successful at six weeks and 82% are successful at two years in reducing a medication. My use tends to be in mild to moderate glaucoma and not end-stage disease. With an abundance of treatment options, it is possible to successfully control glaucoma without diminishing the patient’s quality of life or prospects for future treatment..." read more
December 2, 2018 via @iridex_corporation
Try this laser before you go to the OR - Blog by Dr. Melissa Toyos
In a recent Ocular Surgery News blog post, Dr. Melissa Toyos of Toyos Clinic shares why she uses the Cyclo G6 Glaucoma Laser to treat glaucoma before going to the OR. Dr. Toyos says, "because we work so extensively with dry eye patients, I turn to laser first for glaucoma treatments. If I need to lower IOP further, I go straight to MicroPulse transscleral cyclophotocoagulation (MP-TSCPC) with the Cyclo G6 Laser. With MP-TSCPC, I can lower IOP roughly equivalent to two to three medications, which is generally equivalent to doing a trabeculectomy without the OR time or lengthy post op recovery. Most of my patients can avoid interventional surgery with this approach..." read more